DEcompensated CIrrhoSIs: identification of new cOmbiNatorial therapies based on systems approaches

Project duration

5.5 years

Funding

6.0 million €

Countries

10

Kickoff

1st April 2020
The objective of the DECISION project is to enhance the understanding of the pathophysiology of decompensation of cirrhosis leading to acute-on-chronic liver failure (ACLF) or death. This consortium will take advantage of already existing large and clinically well characterized cohorts to ultimately develop prognostic and response tests and combinatorial therapies tailored to the needs of individual patients to decrease the risk of short-term death.

objectives

  • Systems level elucidation of the pathophysiology of acute decompensation of cirrhosis at multiple levels (genetic, epigenetic, transcriptomic, metabolomics, lipidomics, miR, and extracellular vesicles)
  • Integration of existing clinical data and new multi-omics data from 2,200 patients with more than 8,600 measurements
  • Development of new combinatorial therapies
  • Optimization of therapies using existing and newly developed animal models
  • Development of new tests for prediction of outcome and response to new therapies
  • Phase II clinical trial to test new combination therapies
  • Creation of new guidelines for prediction and treatment of acute decompensation of cirrhosis to prevent ACLF and death

Impact

Scientific research and work will mainly be driven by five overall project goals:
  • Mortality decline
  • Limit side effects
  • Reduction of economic burden
  • Gain intellectual property
  • Providing market opportunity

Scientific coordination

European Foundation For the Study of Chronic Liver Failure
Prof. Pierre-Emmanuel Rautou
Travessera de Gràcia, 11, 7th floor
08021 Barcelona, Spain

Project management

concentris research management GmbH
Fürstenfeldbruck, Germany
Phone: +49 8141 6252 8570

Contact

info@decision-for-liver.eu

Project partners
(Click for members list)